share_log

3.1% Earnings Growth Over 1 Year Has Not Materialized Into Gains for Shinva Medical InstrumentLtd (SHSE:600587) Shareholders Over That Period

3.1% Earnings Growth Over 1 Year Has Not Materialized Into Gains for Shinva Medical InstrumentLtd (SHSE:600587) Shareholders Over That Period

一年內3.1%的收益增長並未爲信華醫療儀器股份有限公司(SHSE:600587)的股東帶來任何收益。
Simply Wall St ·  07/04 20:13

The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. Investors in Shinva Medical Instrument Co.,Ltd. (SHSE:600587) have tasted that bitter downside in the last year, as the share price dropped 42%. That's well below the market decline of 17%. Longer term shareholders haven't suffered as badly, since the stock is down a comparatively less painful 23% in three years. More recently, the share price has dropped a further 15% in a month.

受益於上漲的市場最簡單的方法就是購買指數基金。積極的投資者旨在購買遠遠超過市場表現的股票,但不幸的是,在此過程中,他們冒着低於市場表現的風險。在過去的一年裏,新華醫療(SHSE:600587)的投資者已經嚐到了這種苦澀的下跌,股價下跌了42%,遠遠低於市場下跌了17%。更長期的股東並沒有遭受那麼嚴重的損失,因爲股票在三年內下跌了23%,相對較輕微。最近,股票價格在一個月內又下跌了15%。

If the past week is anything to go by, investor sentiment for Shinva Medical InstrumentLtd isn't positive, so let's see if there's a mismatch between fundamentals and the share price.

如果過去一週是參考的話,新華醫療股份有限公司的投資者情緒並不樂觀,因此讓我們看看基本面和股票價格之間是否存在不匹配。

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

雖然一些人仍然相信有效市場假說,但已經證明市場是過度反應的動態系統,投資者並不總是理性的。一個不完美但簡單的方法來考慮公司市場看法的變化是比較每股收益(EPS)的變化和股價的波動。

Even though the Shinva Medical InstrumentLtd share price is down over the year, its EPS actually improved. It's quite possible that growth expectations may have been unreasonable in the past.

儘管新華醫療股份有限公司的股票價格在過去一年中下跌,但其每股收益實際上有所改善。過去的增長預期可能過高,這是有可能的。

By glancing at these numbers, we'd posit that the the market had expectations of much higher growth, last year. But other metrics might shed some light on why the share price is down.

通過查看這些數字,我們可以假設去年市場對增長有更高的期望。但其他指標可能會解釋股價下跌的原因。

Shinva Medical InstrumentLtd managed to grow revenue over the last year, which is usually a real positive. Since the fundamental metrics don't readily explain the share price drop, there might be an opportunity if the market has overreacted.

新華醫療股份有限公司在過去一年中實現了營業收入增長,這通常是非常積極的。由於基本指標並不能立即解釋股價下跌,如果市場反應過度,可能就會有機會。

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

下圖顯示了收益和營收隨時間變化的情況(如果你點擊圖像,可以看到更多細節):

earnings-and-revenue-growth
SHSE:600587 Earnings and Revenue Growth July 5th 2024
營收每股收益預測數據更新時間截至2024年7月5日SHSE:600587

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

資產負債表強度至關重要。查看我們關於其財務狀況如何隨時間變化的免費報告可能很值得一看。

A Different Perspective

不同的觀點

We regret to report that Shinva Medical InstrumentLtd shareholders are down 40% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 17%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Longer term investors wouldn't be so upset, since they would have made 3%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand Shinva Medical InstrumentLtd better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Shinva Medical InstrumentLtd , and understanding them should be part of your investment process.

遺憾的是,新華醫療股份有限公司的股東今年股價下跌了40%(甚至包括分紅派息)。不幸的是,這比更廣泛的市場下跌17%還要糟。話雖如此,在下跌的市場中,一些股票註定會被超賣。關鍵是緊盯基本發展情況。長期投資者不會那麼難過,因爲他們每年都會獲得3%的利潤,連續五年。如果基本數據繼續表明長期可持續增長,那麼目前的拋售可能值得考慮。長期跟蹤股價表現總是很有趣的。但是爲了更好地了解新華醫療,我們需要考慮許多其他因素。比如說,不可避免的投資風險。我們已經發現了1個關於新華醫療的警告標誌,了解它們應該是您投資過程的一部分。

Of course Shinva Medical InstrumentLtd may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

當然,新華醫療股份有限公司可能不是最好的購買股票。因此,您可能希望查看這個免費的成長股票集合。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論